Form 4: CEO Daniel Virnich Sells TOI Shares for Tax Obligations

The Oncology Institute CEO Daniel Virnich disposed of 23,058 shares to cover tax liabilities related to RSU vesting.

Summary

• CEO Daniel Virnich sold 23,058 shares of The Oncology Institute, Inc. (TOI) common stock.
• The transaction occurred on May 21, 2026, at a price of $4.47 per share.
• The sale was executed to satisfy tax withholding obligations resulting from the vesting of a Restricted Stock Unit (RSU) award granted on May 21, 2024.
• Following this transaction, the CEO retains beneficial ownership of 2,337,166 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the share disposal was a routine administrative action to satisfy tax obligations rather than a discretionary divestment.

Positives

• The transaction was a mandatory tax-related sell-to-cover, not a discretionary market sale, indicating continued long-term alignment with company performance.

Negatives

• The reduction in direct share ownership by the CEO, albeit for tax purposes, decreases the total equity stake held by executive leadership.

Risks

• Reliance on equity-based compensation for executive retention may lead to periodic selling pressure on the stock as awards vest.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this regulatory filing.

Management Comments

• The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard corporate governance practices for executives receiving equity compensation and generally do not signal a change in management sentiment regarding company prospects.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices in the healthcare and biotech sectors, where RSU vesting often triggers automatic tax withholding sales.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax-related sale.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

The Oncology Institute, TOI, Insider Trading, Form 4, Executive Compensation, Daniel Virnich